Dr. Jonathan Trent on FDA Approval of Trabectedin for Soft Tissue Sarcomas
14 Visualizações
administrator
07/18/23
Jonathan C. Trent, MD, professor of Medicine, co-director, Musculoskeletal Center, Sarcoma Medical Research Program, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the FDA approval of trabectedin for patients with soft tissue sarcomas.
Mostre mais
Comentários do Facebook
Nenhum comentário encontrado